drugset / Trial / NCT01469611
A Trial of JX-594 in Refractory Colorectal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to: * determine the maximally-tolerated dose (MTD) and/or maximum-feasible dose (MFD) of JX-594 administered by biweekly intravenous (IV) infusion. * determine the safety of JX-594(TK- GM-CSF+ Wyeth strain vaccinia) administered by biweekly IV infusion.
Timeline
- Start
- 2010-07
- Primary completion
- 2012-10
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pexastimogene Devacirepvec | Other / unclassified | 1e+06 unknown | Intravenous |
| Subject | Pexastimogene Devacirepvec | Other / unclassified | 1e+07 unknown | Intravenous |
| Subject | Pexastimogene Devacirepvec | Other / unclassified | 3e+07 unknown | Intravenous |